Publications

September–October 2020
Article

Social-Impact Efforts That Create Real Value

By: George Serafeim

Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create... View Details

Find at Harvard

Read Now

Research Summary

Regulatory Change/Business-Government Relations

“Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

Keywords: Business ＆ Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States

15 Jan 2008
First Look

First Look: January 15, 2008

across complements can offset horizontal competition between substitutes. In this paper, we isolate the offsetting price effects and show how they operate in large (as well as small) clusters. We argue that it is possible in principle for... View Details

Keywords: Martha Lagace

21 Apr 2009
First Look

First Look: April 21, 2009

competitive standing of their domestic pharmaceutical industries. Download the paper: http://www.hbs.edu/research/pdf/09-118.pdf Capitalizing On Innovation: The Case of Japan Authors:Robert Dujarric and... View Details

Keywords: Martha Lagace

January 1999
Background Note

Note on the Drugstore Industry

By: David E. Bell and Ann Leamon

In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details

Keywords: History; Industry Growth; Pharmaceutical Industry; Pharmaceutical Industry

2001
Other Unpublished Work

Clusters of Innovation Initiative: San Diego

By: Michael E. Porter

The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details

Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego

Read Now

15 May 2007
First Look

First Look: May 15, 2007

Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907412 HDFC (A) Harvard Business School Case 301-093 The top management team at India's leading home finance company must decide how to deal with the emergence of intense View Details

Keywords: Martha Lagace

William E. Fruhan

Professor WILLIAM E. FRUHAN, JR. is George E. Bates Professor, Emeritus at the Harvard Business School. He received his BS degree from Yale University, and his MBA and DBA degrees from Harvard University. He has served as Senior Associate Dean and Director of... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

February 2018 (Revised April 2018)
Case

Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise

By: Michael Chu, William C. Kirby, Nancy Hua Dai and Yuanzhuo Wang

This case tells the story of how Wang Minghui, Chairman of Yunnan Baiyao Group since 1999, transformed a single-product traditional Chinese medicine (TCM) state-owned enterprise (SOE) into a major diversified consumer health player in China's highly competitive... View Details

Keywords: State-owned Enterprise (SOE); Traditional Chinese Medicine; Yunnan; Yunnan Baiyao; Consumer Health; Enterprise Transformation; Transformation; Health; Business History; State Ownership; Private Ownership; Business Strategy; Commercialization; Competition; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; China

Stefan Thomke (sthomke@hbs.edu), an authority on the management of innovation, is the William Barclay Harding Professor of Business Administration at Harvard Business School. He has worked with firms on product, process, and... View Details

April 1989 (Revised January 1994)
Case

Novo Industri

By: Michael E. Porter and Michael J. Enright

Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an... View Details

Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry

Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details

01 Jun 2009
Lessons from the Classroom

The Challenges of Investing in Science-Based Innovation

In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term View Details

Keywords: by Julia Hanna; Pharmaceutical; Pharmaceutical; Pharmaceutical

21 Feb 2018
Research & Ideas

When a Competitor Abandons the Market, Should You Advance or Retreat?

Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details

Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical

February 2010 (Revised April 2010)
Case

Organization and Strategy at Millennium (A)

By: Julie M. Wulf and Scott Waggoner

This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details

Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry

10 Oct 2007
First Look

First Look: First Look: October 10

Hamermesh, Faculty Chair of the Harvard Business Healthcare Initiative, discuss the barriers to personalized medicine and suggest ways to overcome them. The blockbuster model for developing drugs, the authors point out, is still what most major View Details

Keywords: Martha Lagace

Roberto Verganti

Roberto Verganti (rverganti@hbs.edu) is in the Technology and Operations Management Unit at Harvard Business School. He teaches Design Theory and Practice for the View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

February 2010
Supplement

Organization and Strategy at Millennium (B)

By: Julie M. Wulf and Scott Waggoner

This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details

Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry